A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 34, Issue 3, 2001, Pages 427-432

  Kim, Edward S ^a   Lu, Charles ^a   Khuri, Fadlo R ^a   Tonda, Margaret ^b   Glisson, Bonnie S ^a   Liu, Diane ^a   Jung, Maria ^a   Hong, Waun Ki ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ALZA CORPORATION   (United States)

Author keywords

Cisplatin; Liposome; Non small cell lung cancer; Second line therapy

Indexed keywords

CISPLATIN; LIPOSOME; MITOPODOZIDE; PLATINUM DERIVATIVE; STEALTH LIPOSOME; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; LUNG TUMOR; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; FEMALE; HUMAN; LIPOSOMES; LUNG NEOPLASMS; MALE; MIDDLE AGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034760098     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00278-1     Document Type: Article

References (20)

1. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [abstract]
2. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
3. Summary of phase II data of docetaxel, an active agent in the first-line and second-line treatment of advanced non-small cell lung cancer
4. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group
5. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
6. Carboplatin. A preliminary review of its pharmacokinetic properties and therapeutic efficacy in the treatment of cancer
7. Clinical pharmacokinetics of carboplatin
8. Biological properties of sterically stabilized liposomes
9. Light microscopic localization of silver-enhanced liposome-entrapped colloidal gold in mouse tissues
10. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice
11. A Phase I study of Stealth (Cisplatin (SPI-77) and vinorelbine in patients with advanced non-small cell lung cancer
12. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
13. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
14. Phase I trial of SPI-77 plus paclitaxel (P) in patients with refractory non-small cell lung cancer (NSCLC) [abstract]
15. Phase I and pharmacologic study of Stealth (Liposomal Encapsulated Cisplatin (SPI-77)) [abstract]
16. A phase I and pharmacokinetic study in pediatric patients of cisplatin encapsulated in Stealth Liposomes (SPI-77)) [abstract]
17. A phase I study of Liposome-Formulated Cisplatin (SPI-77 R) given every 3 weeks in patients with advanced cancer) [abstract]